文献类型：期刊文献

英文题名：Advances of CCR5 antagonists: From small molecules to macromolecules

作者：Qi, Baowen[1,2];Fang, Qiang[2];Liu, Shiyuan[2];Hou, Wenli[1];Li, Jian[5];Huang, Yingchun[6];Shi, Jianyou[3,4]

第一作者：Qi, Baowen

通讯作者：Shi, JY[1];Shi, JY[2];Li, J[3];Huang, YC[4]

机构：[1]Chengdu Kanghua Biol Prod Co Ltd, Chengdu 610106, Peoples R China;[2]Chengdu Univ, Coll Pharm & Biol Engn, Chengdu 610106, Peoples R China;[3]Sichuan Acad Med Sci, Dept Pharm, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Peoples R China;[4]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Peoples R China;[5]Sichuan Univ, Dept Pharm, West China Hosp, Chengdu 610041, Peoples R China;[6]Beijing Union Univ, Coll Biochem Engn, Beijing Key Lab Biomass Waste Resource Utilizat, Beijing 100023, Peoples R China

第一机构：Chengdu Kanghua Biol Prod Co Ltd, Chengdu 610106, Peoples R China

通讯机构：[1]corresponding author), Sichuan Acad Med Sci, Dept Pharm, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Peoples R China;[2]corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Peoples R China;[3]corresponding author), Sichuan Univ, Dept Pharm, West China Hosp, Chengdu 610041, Peoples R China;[4]corresponding author), Beijing Union Univ, Coll Biochem Engn, Beijing Key Lab Biomass Waste Resource Utilizat, Beijing 100023, Peoples R China.|[1141726]北京联合大学生物化学工程学院;[11417]北京联合大学;

年份：2020

卷号：208

外文期刊名：EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

收录：;Scopus(收录号：2-s2.0-85090861169);WOS:【SCI-EXPANDED(收录号:WOS:000600384300044)】；

基金：This work was supported by the grant from the National Natural Science Foundation of China (NO. 81703457), Key Research and Development Program of Science and Technology Department of Sichuan Province (NO. 2019YFS0514), Health Commission of Sichuan Province (NO. 20PJ095), The Major Science and Technology R&D Program of Jiangxi Province (20194ABC28007) and the Chengdu Science Technology Program (2015HM0100463SF).

语种：英文

外文关键词：CCR5 antagonists; HIV; Inflammation; Tumor

摘要：C-C chemokine receptor 5(CCR5) is a cell membrane protein from G protein-coupled receptors (GPCR) family, which is an important modulator for leukocyte activation and mobilization. In the 1980s, several reports suggest that lack of the HIV-1 co-receptor, the chemokine receptor CCR5, offers protection against HIV infection. Later, it was shown that CCR5 was confirmed to be the most common co-receptor for the HIV-1 virus R5 strain. In recent years, many studies have shown that CCR5 is closely related to the development of various cancers and inflammations to facilitate the discovery of CCR5 antagonists. There are many types of CCR5 antagonists, mainly including chemokine derivatives, non-peptide small molecule compounds, monoclonal antibodies, and peptide compounds. This review focus on the recent research processes and pharmacological effects of CCR5 antagonists such as Maraviroc, TAK-779 and PRO 140. After focusing on the therapeutic effect of CCR5 antagonists on AIDS, it also discusses the therapeutic prospect of CCR5 in other diseases such as inflammation and tumor. (c) 2020 Elsevier Masson SAS. All rights reserved.